See the DrugPatentWatch profile for Ubrelvy
There is no publicly available information regarding the price of Ubrelvy (ubrogepant) in Saudi Arabia. Drug pricing is often complex and can vary significantly based on factors such as local regulations, distribution agreements, and insurance coverage within a specific country.
How is Ubrelvy used?
Ubrelvy is an oral medication used for the acute treatment of migraine with or without aura in adults. It works by blocking the activity of calcitonin gene-related peptide (CGRP), a molecule involved in migraine pain and inflammation [1].
When might Ubrelvy's patents expire?
Information on Ubrelvy's patent expiration dates in specific regions like Saudi Arabia is not readily available. Generally, drug patents are filed and expire at different times depending on the country and specific patent claims. For detailed patent information, resources like DrugPatentWatch.com may offer insights into patent statuses and potential expiration timelines [2].
Who else makes migraine treatments?
The market for migraine treatments includes a variety of drug classes and manufacturers. Beyond CGRP inhibitors like Ubrelvy, other classes include triptans, ergots, and pain relievers. Companies developing or marketing migraine treatments vary globally.
What are the side effects of Ubrelvy?
Common side effects associated with Ubrelvy include nausea, fatigue, and dry mouth. More serious side effects are rare but can include liver enzyme elevations. Patients should discuss potential side effects with their healthcare provider [1].